We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+16.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$593M
AUM Growth
+$248M
Cap. Flow
+$187M
Cap. Flow %
31.46%
Top 10 Hldgs %
30.55%
Holding
100
New
16
Increased
48
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$12.8M
3
NKTR icon
Nektar Therapeutics
NKTR
+$10.4M
4
UHS icon
Universal Health Services
UHS
+$9.62M
5
AMGN icon
Amgen
AMGN
+$9.42M

Top Sells

Rank Stock Value
1
UTI icon
Universal Technical Institute
UTI
+$6.79M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$5.83M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.37M
5
CELG
Celgene Corp
CELG
+$3.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.68%
2 Financials 0.74%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$132B
$8.32M 1.4%
129,000
+14,000
+12% +$876K
RCPT
27
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$7.17M 1.21%
43,500
-9,026
-17% -$1.14M
BHC icon
28
Bausch Health
BHC
$2.34B
$7.15M 1.21%
+36,000
New +$6.39M
CYBX
29
DELISTED
CYBERONICS INC
CYBX
$7.01M 1.18%
108,000
+68,000
+170% +$4.14M
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$126B
$6.84M 1.15%
58,000
+20,000
+53% +$2.4M
BDX icon
31
Becton Dickinson
BDX
$48.2B
$6.75M 1.14%
48,157
+27,511
+133% +$3.85M
OREX
32
DELISTED
Orexigen Therapeutics, Inc.
OREX
$6.51M 1.1%
83,180
+45,680
+122% +$2.83M
IONS icon
33
Ionis Pharmaceuticals
IONS
$9.4B
$6.49M 1.1%
102,000
+60,000
+143% +$4.07M
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.49M 1.09%
23,000
+1,000
+5% +$217K
CEMP
35
DELISTED
Cempra, Inc.
CEMP
$6.36M 1.07%
+185,300
New +$5.57M
CYH icon
36
Community Health Systems
CYH
$423M
$6.17M 1.04%
142,780
+65,340
+84% +$2.71M
ACAD icon
37
Acadia Pharmaceuticals
ACAD
$5.03B
$5.57M 0.94%
171,000
+6,000
+4% +$206K
HCA icon
38
HCA Healthcare
HCA
$89.5B
$5.57M 0.94%
74,000
+33,000
+80% +$2.37M
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.53M 0.93%
53,000
+30,000
+130% +$3.04M
SUPN icon
40
Supernus Pharmaceuticals
SUPN
$2.77B
$5.45M 0.92%
450,800
+200,000
+80% +$1.89M
MDT icon
41
Medtronic
MDT
$112B
$5.38M 0.91%
69,000
+34,000
+97% +$2.58M
LH icon
42
Labcorp
LH
$25.9B
$4.92M 0.83%
+45,396
New +$4.67M
RVNC
43
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.89M 0.82%
236,000
+109,426
+86% +$1.89M
CERN
44
DELISTED
Cerner Corp
CERN
$4.83M 0.82%
66,000
+28,000
+74% +$1.94M
DXCM icon
45
DexCom
DXCM
$32B
$4.8M 0.81%
308,000
+52,000
+20% +$786K
AMSG
46
DELISTED
Amsurg Corp
AMSG
$4.68M 0.79%
76,000
+29,000
+62% +$1.67M
TTPH
47
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.47M 0.75%
+6,100
New +$4.58M
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.37M 0.74%
183,000
+23,146
+14% +$518K
AET
49
DELISTED
Aetna Inc
AET
$4.37M 0.74%
41,000
+13,000
+46% +$1.27M
COR icon
50
Cencora
COR
$61.2B
$4.32M 0.73%
38,000
-2,000
-5% -$201K
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rhenman & Partners Asset Management held 100 positions worth $593M, up 72% from $345M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $187M of net new capital in Q1 2015, opening 16 new positions and adding to 48 existing holdings. Its largest new stake was Universal Health Services: 87,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $4.79M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2015 buy was Universal Health Services: 87,000 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Merck in Q1 2015, an estimated $13.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $4.79M.
  • Rhenman & Partners Asset Management fully exited Universal Technical Institute in Q1 2015, selling an estimated $6.79M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $593M portfolio in Q1 2015.
  • Rhenman & Partners Asset Management opened 16 new positions and closed 11 in Q1 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 72% quarter-over-quarter to $593M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2015, filed 13 May 2015.